52 results about "Clonidine" patented technology

The present invention provides compositions for transdermal pain relief. According to one embodiment, a transdermal composition for the relief of pain in a subject comprising: amitriptyline, clonidine, ketamine and an anti-inflammatory in a base having at least ten percent (10%) lecithin isopropyl palmitate oil (lipoil).

Implantable osmotic pump devices and systems include multiple osmotic pumps and / or semipermeable membranes to extend the useful life cycle and functionality of the drug delivery system. Use of an implantable system including multiple implantable osmotic pumps allows different drugs to be administered from the same implanted system. One or more of the semipermeable membranes of the system may be initially sealed by an overlying impermeable membrane upon implantation of the system into the patient. When the patient develops a tolerance to a first drug or to a first dose of the first drug, the impermeable membrane may be breached, to expose the underlying semipermeable membrane to the osmotic pressure of the patient at the implant site. This causes the infusion rate to increase, thereby providing the patient with the needed relief and / or other desired therapeutic effect. In the case of a multiple pump system, breaching an impermeable membrane may cause the infusion of a second drug. The second drug may potentiate a therapeutic effect (such as an analgesic effect) of the first drug, as is the case with Sufentanil and Clonidine.

The present invention is direct to a method of producing analgesia in a mammalian subject. The method includes administering to the subject an omega conopeptide, preferably ziconotide, in combination with an analgesic selected from the group consisting of morphine, bupivicaine, clonidine, hydromorphone, baclofen, fentanyil, buprenorphine, and sufentanil, or its pharmaceutically acceptable salts thereof, wherein the ω-conopeptide retains its potency and is physically and chemically compatible with the analgesic compound. A preferred route of administration is intrathecal administration, particularly continuous intrathecal infusion. The present invention is also directed to a pharmaceutical formulation comprising an omega conopeptide, preferably ziconotide, in combination with an analgesic selected from the group consisting of morphine, bupivicaine, clonidine, hydromorphone, baclofen, fentanyl, buprenorphine, and sufentanil.

The invention mainly relates to the field of cultivation and discloses a cotton breeding matrix. The cotton breeding matrix is prepared from cotton straws, corn stalks, wheat straws, biogas residues, sweet potato residues, Potamogeton crispus, cow dung, edible fungus wastes, EM bacteria, traditional Chinese medicines, clonidine, rose flower extract, river sand, vermiculite and medical stone. The cotton breeding matrix is prepared from abundant raw materials, has balanced nutrition, can provide the necessary nutrients for cotton growth, has antibacterial and insecticidal effects, enhances the disease resistance of cotton, and realizes an emergence rate of cotton of 89%, a survival rate of 94%, a disease and pest rate of 4% and economic efficiency of 9.6%. Cotton straw as a raw material is fully used and application approaches of clonidine and rose flower extract are increased. Through strain culture fermentation and use of medical stone rich in small molecule beneficial ingredients, the growth of cotton is promoted, a planting period is shortened by 15 to 20 days and planting efficiency is accelerated. Through cooperation of medical stone and a variety of Chinese herbal medicines, the cotton breeding matrix inhibits occurrence of pests and diseases, reduces an incidence rate of pests and diseases and saves a planting cost.

The invention relates to an active substance combination consisting of clonidine and pramipexole for treating Restless Leg Syndrome.

The present invention is directed to an implantable drug depot useful for reducing, preventing or treating post-operative pain in a patient in need of such treatment, the implantable drug depot comprising a therapeutically effective amount of clonidine or pharmaceutically acceptable salt thereof and a polymer; wherein the depot is implantable at a site beneath the skin to reduce, prevent or treat post-operative pain, and the depot is capable of releasing (i) about 5% to about 45% of the clonidine or pharmaceutically acceptable salt thereof relative to a total amount of the clonidine or pharmaceutically acceptable salt thereof loaded in the drug depot over a first period of up to 48 hours and (ii) about 55% to about 95% of the clonidine or pharmaceutically acceptable salt thereof relative to a total amount of the clonidine or pharmaceutically acceptable salt thereof loaded in the drug depot over a subsequent period of at least 3 days.

The invention discloses a detoxification plaster with clonidine and the related preparation method used for curing opioid and tobacco-dependentance. The detoxification plaster is structurally composed of a protective layer, an adhesive layer, a control release membrane layer, a medicine storehouse layer and a back lining layer. The ingredients of the preparation are that: the medicine storehouse layer contains 10 to 40 percent of clonidine and 0 to 20 percent of transdermal enhancer and the rest are soluble or non-soluble substrates; the adhesive layer contains 0 to 30 percent of clonidine and 2 to 20 percent of transdermal enhancer and the rest is pressure-sensitive adhesive; the back lining layer is a PET membrane or a non-woven fabric; the protective layer is a PET film processed with antisticking treatment; the control release membrane is an EVA polymer membrane. The area of each plaster is 1-5square centimeters; each plaster contains 1mg to 5mg of clonidine. The invention is not addictive but fast in effect, high in cure rate and safe and convenient. The external release of the invention reaches zero-degree rate process.

Effective treatments of dystonia and / or post-stroke spasticity for extended periods of time are provided. Through the administration of an effective amount of clonidine at or near a target site, one can relieve dystonia and / or post-stroke spasticity caused by diverse sources. When appropriate formulations are provided within biodegradable polymers, this relief can be continued for at least five days. In some embodiments, the relief can be for at least twenty-five days, at least fifty days, at least one hundred days, at least one hundred and thirty-five days or at least one hundred and eighty days.

This invention discloses that a combination of two drugs, from two different and previously unrelated categories, provides effective and long-lasting relief from neuropathic pain. Both drugs can be taken orally, in a convenient, painless, non-invasive manner that does not require injections. One drug in this combination is an alpha2 adrenergic agonist, exemplified by clonidine. The other drug in the pain-relieving combination has a tri-cyclo-alkyl-amine (TCAA) structure. At least some TCAA drugs have antagonist (receptor-blocking) activity at two entirely different classes of neuronal receptors: the muscarinic subclass of acetylcholine (ACh) receptors, and the NMDA subclass of glutamate receptors. Such drugs include ethopropazine, normally used as an anti-cholinergic drug, and desipramine, normally used as an anti-depressant. Tests by the Applicants have shown that at least some TCAA drugs can relieve neuropathic pain to a limited extent, but at the doses required to relieve pain, they cause adverse side effects, and any pain relief is relatively brief and short-lived. However, when a TCAA drug such as ethopropazine is administered together with an alpha2 adrenergic agonist such as clonidine, these drugs mutually potentiate one another's neuropathic pain-relieving action, and provide potent and sustained neuropathic pain relief, even when each agent is administered at a low dosage that is below its threshold for causing adverse side effects. Accordingly, this drug combination can provide safe and effective relief of neuropathic pain and possibly other types of chronic and / or intractable pain, at dosages which are so low that they do not pose serious risks of adverse side effects.